BPC/TB500 Blend 10mg/10mg

Visao Geral

BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) e um(a) sintetico(a) pentadecapeptide composto(a) por 15 aminoacidos (GEPPPGKPADDAGLV), derivado(a) de a partial sequence of a larger Body Protection Compound protein naturally encontrado(a) em human gastric juice.[1][2]

Originally isolado(a) by Dr. Predrag Sikiric's grupo de pesquisa no(a) University of Zagreb in 1993, BPC-157 is one do(a) a maioria extensively studied cytoprotective peptides in preclinical literature. It demonstra pleiotropic effects across gastrointestinal, musculoskeletal, neurological, and vascular models.[8]

A key distinguishing feature is its exceptional stability — BPC-157 resists enzymatic degradacao in human gastric juice for over 24 hours, is eficaz via multiplos(as) routes (oral, parenteral, topical) sem requiring a carrier molecule, and has shown no lethal dose (LD1) in toxicology studies.[3][9]

The U.S. FDA placed BPC-157 no(a) Categoria 2 Substancia Farmaceutica a Granels list in September 2023, citing potential immunogenicity risks and insufficient safety data for human manipulacao.[4] WADA explicitly banned BPC-157 under S0 (Non-approved Substances) eficaz January 1, 2022.[5]

Mecanismo de Acao

VEGFR2 Activation (Primary Target)

BPC-157 liga-se a and ativa vascular endothelial fator de crescimento receptor 2 (VEGFR2) on celulas endoteliais. Diferentemente de standard ligands, BPC-157 promove VEGFR2 internalizacao — um(a) critico(a) step in activating downstream repair pathways.[7][10]

Src Family Kinase Activation

A 2025 study proposes que BPC-157 adopts a polyproline II helix structure que engages the SH3 domains of Src family kinases (c-Src, Yes, Fyn), relieving autoinibicao and acting como um(a) intracellular "switch" for signal transduction.[11]

VEGFR2-Akt-eNOS Cascade

Upon VEGFR2 binding, BPC-157 desencadeia fosforilacao of Akt (Protein Kinase B), que ativa endothelial nitric oxide synthase (eNOS), producing nitric oxide (NO) — essencial para angiogenese and vascular repair.[7]

Src-Caveolin-1-eNOS Pathway

BPC-157 promove fosforilacao of Src and Caveolin-1 (Cav-1). Under normal conditions, Cav-1 inibe eNOS — BPC-157 disrupts this inhibitory complex, enhancing NO production.[10]

FAK-Paxillin Pathway

In tendon fibroblastos, BPC-157 ativa focal adhesion kinase (FAK) and paxillin, essencial para migracao celular, adhesion, and cytoskeletal organization during reparo tecidual.[12]

JAK-2 / Growth Hormone Receptor Upregulacao

BPC-157 ativa JAK-2, linked to upregulacao of hormonio do crescimento receptors (GHR) on tendon fibroblastos, enhancing tissue sensitivity to hormonio do crescimento.[12][13]

Egr-1/NAB2 Feedback Loop

ERK1/2 ativacao upregula Egr-1 and simultaneamente its corepressor NAB2, establishing a feedback loop que previne uncontrolled angiogenic signaling.[14]

Nitric Oxide System Modulation (Bidirectional)

BPC-157 exibe um(a) unico(a) modulatory interaction com o(a) NO system — it counteracts ambos(as) L-NAME (NOS inhibitor → hipertensao) and L-arginine (NOS substrate → hipotensao), acting como um(a) homeostatic buffer rather do que a strict agonist or antagonist.[15]

Dopamine/Serotonin System Regulation

BPC-157 antagonizes o efeitos of dopamine receptor blockers (haloperidol) and agonists (amphetamine), assim como serotonin syndrome precursors — suggesting a regulatory influence on these neurotransmitter systems rather do que direto(a) ligacao ao receptor.[16]

Aplicacoes de Pesquisa

BPC-157 demonstra pleiotropic effects across multiplos(as) experimental paradigms, with unusually broad tissue coverage for a single peptide:

1. Gastrointestinal Healing — Anti-ulcer peptidergic agent eficaz against IBD, ulcerative colitis, NSAID-induziu lesions, and complex fistulas. Phase II human data available (n=53, ulcerative colitis).[6]
2. Musculoskeletal Regeneration — Accelerated healing of transected/detached tendons (Achilles, quadriceps), ligaments (MCL), and musculo esqueletico injuries. Improved biomechanical function and reversed corticosteroid impairment.[17][18]
3. Neuroprotection and CNS Repair — Protective in models of TBI, spinal cord compression, and bilateral carotid occlusion. Reduced edema, neuronal necrose, desmielinizacao. Functional recovery manteve to 1 year (spinal cord).[19][20]
4. Vascular Occlusion Models — Rapidly ativa collateral vessels to bypass occlusions (Budd-Chiari syndrome, Pringle maneuver). Prevents thrombotic/ischemic damage and preserva organ function.[21]
5. Corneal Healing — Maintains corneal transparency and acelera ulcer/perforation healing sem inducing neovascularizacao (unicamente anti-angiogenic in cornea).[22]
6. Hepatoprotection — Protective against alcohol/NSAID-induziu liver injury, fibrose, and cirrhosis. Normalized liver enzymes and bilirubin in bile duct ligation models.[23]
7. Pain Management — Human pilot data: intra-articular injection (2 mg) for knee pain (91.6% significant improvement, n=16) and intravesical injection (10 mg) for interstitial cystitis (83.3% complete resolution, n=12).[24][25]
8. Dopaminergic/Serotonergic Modulation — Efficacy in models of schizophrenia and depression; counteracted catalepsy, amphetamine-induziu hyperactivity, and ketamine-induziu "negative-like" symptoms.[16]

Resumo da Pesquisa Pre-clinica

Key Preclinical Studies

Clinical / Human Studies

Parametros Farmacocineticos